BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35452997)

  • 1. The novel pretreatment immune prognostic index discriminates survival outcomes in locally advanced non-operative esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: a 6-year retrospective study.
    Yu Y; Wu H; Qiu J; Ke D; Wu Y; Lin M; Zheng Q; Zheng H; Wang Z; Li H; Liu L; Li J; Yao Q
    Transl Oncol; 2022 Jul; 21():101430. PubMed ID: 35452997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Nutrition-Related Factor-Based Risk Stratification for Exploring the Clinical Benefits in the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Definitive Chemoradiotherapy: A Retrospective Cohort Study.
    Yu Y; Wu H; Qiu J; Ke D; Wu Y; Lin M; Liu T; Zheng Q; Zheng H; Yang J; Wang Z; Li H; Liu L; Yao Q; Li J; Cheng W; Chen X
    Front Nutr; 2022; 9():896847. PubMed ID: 35990358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Model Combining Tumor Length, Tumor Thickness, TNM_Stage, Nutritional Index, and Inflammatory Index Might Be Superior to the 8th TNM Staging Criteria in Predicting the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy.
    Chen X; Yu Y; Wu H; Qiu J; Ke D; Wu Y; Lin M; Liu T; Zheng Q; Zheng H; Yang J; Wang Z; Li H; Liu L; Yao Q; Li J; Cheng W
    Front Oncol; 2022; 12():896788. PubMed ID: 35719969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.
    Cox S; Hurt C; Grenader T; Mukherjee S; Bridgewater J; Crosby T
    Radiother Oncol; 2017 Oct; 125(1):154-159. PubMed ID: 28893415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of pre-therapeutic nutritional risk factors in elderly patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or radiotherapy.
    Qiu J; Yang J; Yu Y; Wang Z; Lin H; Ke D; Zheng H; Li J; Yao Q
    BMC Cancer; 2023 Jun; 23(1):597. PubMed ID: 37380982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A composite indicator of derived neutrophil-lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors.
    Chen S; Guo S; Gou M; Pan Y; Fan M; Zhang N; Tan Z; Dai G
    Front Oncol; 2022; 12():951985. PubMed ID: 36387152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new risk score model based on lactate dehydrogenase for predicting prognosis in esophageal squamous cell carcinoma treated with chemoradiotherapy.
    Liu C; Han J; Han D; Huang W; Li B
    J Thorac Dis; 2023 Apr; 15(4):2116-2128. PubMed ID: 37197526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic values of the gross volume of metastatic lymph nodes in patients with esophageal squamous cell carcinoma treated with definitive concurrent chemoradiotherapy.
    Li Y; Li Y; Huang H; Guo Z; Zhang K; Zhang W; Pang Q; Wang P
    Front Oncol; 2022; 12():996293. PubMed ID: 36439511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Zhou XL; Li YQ; Zhu WG; Yu CH; Song YQ; Wang WW; He DC; Tao GZ; Tong YS
    Sci Rep; 2017 Feb; 7():42581. PubMed ID: 28195186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
    Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
    J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Significance of the Lung Immune Prognostic Index in Patients with Resected Esophageal Squamous Cell Carcinoma.
    Feng JF; Zhao JM; Chen S; Chen QX
    Cancer Manag Res; 2021; 13():2811-2819. PubMed ID: 33814930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.
    Li L; Ai L; Jia L; Zhang L; Lei B; Zhang Q
    BMC Cancer; 2022 Jan; 22(1):29. PubMed ID: 34980025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis.
    Zhang Q; Gong X; Sun L; Miao L; Zhou Y
    Front Oncol; 2022; 12():791496. PubMed ID: 35924149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Albumin and Derived Neutrophil-to-Lymphocyte Ratio is a Novel Prognostic Factor for Patients with Esophageal Squamous Cell Carcinoma.
    Abe T; Oshikiri T; Goto H; Kato T; Horikawa M; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Nakamura T; Kakeji Y
    Ann Surg Oncol; 2022 Oct; 29(11):6860-6866. PubMed ID: 35622180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma.
    Li Y; Wang K; Zhao E; Li B; Li S; Dong X; Yuan L; Yang H
    Pathol Oncol Res; 2022; 28():1610245. PubMed ID: 35721326
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic value of pretreatment prognostic nutritional index and lactated dehydrogenase in locally advanced nasopharyngeal carcinoma patients.
    Xiong Y; Shi LL; Zhu LS; Peng G
    Ann Palliat Med; 2021 Apr; 10(4):4122-4133. PubMed ID: 33832314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients Treated with Definitive Chemoradiotherapy for Locally Advanced Oesophageal Squamous Cell Carcinoma.
    Zhang G; Yang C; Zhao C; Xian F; Qing D; Guo Q; Song J; Liu X; Bie J
    Cancer Manag Res; 2023; 15():101-112. PubMed ID: 36743459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.